Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Exp Immunol ; 190(1): 122-132, 2017 10.
Article in English | MEDLINE | ID: mdl-28543170

ABSTRACT

Cardiomyopathy is the most severe outcome of Chagas disease, causing more than 12 000 deaths/year. Immune cells participate in cardiomyopathy development either by direct tissue destruction, or by driving inflammation. We have shown that CD4- CD8- [double-negative (DN)] T cells are major sources of inflammatory and anti-inflammatory cytokines, associated with the cardiac (CARD) and indeterminate (IND) forms of Chagas disease, respectively. Here, we sought to identify Trypanosoma cruzi-derived components that lead to activation of DN T cells in Chagas patients. Glycolipid (GCL), lipid (LIP) and protein-enriched (PRO) fractions derived from trypomastigote forms of T. cruzi were utilized to stimulate cells from IND and CARD patients to determine DN T cell activation by evaluating CD69 and cytokine expression. We observed that GCL, but not LIP or PRO fractions, induced higher activation of DN T cells, especially T cell receptor (TCR)-γδ DN T, from IND and CARD. GCL led to an increase in tumour necrosis factor (TNF) and interleukin (IL)-10 expression by TCR-γδ DN T cells from IND, while inducing IFN-γ expression by TCR-γδ DN T cells from CARD. This led to an increase in the ratio IFN-γ/IL-10 in TCR-γδ DN T cells from CARD, favouring an inflammatory profile. These results identify GCL as the major T. cruzi component responsible for activation of DN T cells in chronic Chagas disease, associated predominantly with an inflammatory profile in CARD, but not IND. These findings may have implications for designing new strategies of control or prevention of Chagas disease cardiomyopathy by modulating the response to GCL.


Subject(s)
Antigens, Protozoan/immunology , Cardiomyopathies/immunology , Chagas Disease/immunology , Glycolipids/immunology , Inflammation/immunology , T-Lymphocytes/immunology , Trypanosoma cruzi/immunology , Adult , Aged , CD4 Antigens/metabolism , CD8 Antigens/metabolism , Cell Differentiation , Cells, Cultured , Cytokines/metabolism , Disease Progression , Female , Humans , Inflammation Mediators/metabolism , Lymphocyte Activation , Male , Middle Aged , Receptors, Antigen, T-Cell, gamma-delta/metabolism , T-Lymphocytes/microbiology
2.
Parasite Immunol ; 36(8): 377-87, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24611805

ABSTRACT

Chagas disease, caused by the infection with Trypanosoma cruzi, is endemic in all Latin America. Due to the increase in population migration, Chagas disease has spread worldwide and is now considered a health issue not only in endemic countries. While most chronically infected individuals remain asymptomatic, approximately 30% of the patients develop a potentially deadly cardiomyopathy. The exact mechanisms that underlie the establishment and maintenance of the cardiac pathology are not clear. However, there is consistent evidence that immunoregulatory cytokines are critical for orchestrating the immune response and thus influence disease development or control. While the asymptomatic (indeterminate) form represents a state of balance between the host and the parasite, the establishment of the cardiac form represents the loss of this balance. Analysis of data obtained from several studies has led to the hypothesis that the indeterminate form is associated with an anti-inflammatory cytokine profile, represented by high expression of IL-10, while cardiac form is associated with a high production of IFN-gamma and TNF-alpha in relation to IL-10, leading to an inflammatory profile. Here, we discuss the immunoregulatory events that might influence disease outcome, as well as the mechanisms that influence the establishment of these complex immunoregulatory networks.


Subject(s)
Chagas Disease/immunology , Chagas Disease/pathology , Signal Transduction , Trypanosoma cruzi/physiology , Animals , Cytokines/genetics , Cytokines/metabolism , Gene Expression Regulation/immunology , Host-Parasite Interactions/immunology , Humans
3.
Clin Exp Immunol ; 162(3): 528-36, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20964644

ABSTRACT

The anti-hypertensive drug captopril is used commonly to reduce blood pressure of patients with severe forms of Chagas disease, a cardiomyopathy caused by chronic infection with the intracellular protozoan Trypanosoma cruzi. Captopril acts by inhibiting angiotensin-converting enzyme (ACE), the vasopressor metallopeptidase that generates angiotensin II and promotes the degradation of bradykinin (BK). Recent studies in mice models of Chagas disease indicated that captopril can potentiate the T helper type 1 (Th1)-directing natural adjuvant property of BK. Equipped with kinin-releasing cysteine proteases, T. cruzi trypomastigotes were shown previously to invade non-professional phagocytic cells, such as human endothelial cells and murine cardiomyocytes, through the signalling of G protein-coupled bradykinin receptors (B(2) KR). Monocytes are also parasitized by T. cruzi and these cells are known to be important for the host immune response during infection. Here we showed that captopril increases the intensity of T. cruzi infection of human monocytes in vitro. The increased parasitism was accompanied by up-regulated expression of ACE in human monocytes. While T. cruzi infection increased the expression of interleukin (IL)-10 by monocytes significantly, compared to uninfected cells, T. cruzi infection in association with captopril down-modulated IL-10 expression by the monocytes. Surprisingly, studies with peripheral blood mononuclear cells revealed that addition of the ACE inhibitor in association with T. cruzi increased expression of IL-17 by CD4(+) T cells in a B(2) KR-dependent manner. Collectively, our results suggest that captopril might interfere with host-parasite equilibrium by enhancing infection of monocytes, decreasing the expression of the modulatory cytokine IL-10, while guiding development of the proinflammatory Th17 subset.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/pharmacology , CD4-Positive T-Lymphocytes/drug effects , Captopril/pharmacology , Chagas Disease/drug therapy , Monocytes/drug effects , Trypanosoma cruzi/immunology , Adult , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/metabolism , CD4-Positive T-Lymphocytes/parasitology , CD4-Positive T-Lymphocytes/pathology , Cells, Cultured , Chagas Disease/immunology , Chagas Disease/parasitology , Chagas Disease/physiopathology , Gene Expression Regulation , Host-Parasite Interactions/drug effects , Humans , Inflammation Mediators/metabolism , Interleukin-10/biosynthesis , Interleukin-10/genetics , Interleukin-17/genetics , Interleukin-17/metabolism , Male , Monocytes/immunology , Monocytes/metabolism , Monocytes/parasitology , Monocytes/pathology , Renin-Angiotensin System/drug effects , Th1-Th2 Balance , Trypanosoma cruzi/pathogenicity , Virulence/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...